The Molecular Oncology Program of the University of California, Davis Cancer Center is focused on understanding fundamental processes associated with carcinogenesis and the molecular and cell biology of cancer cells. Within this framework the program integrates two distinct but related and mutually reinforcing areas, oncogenic signals and chromosome biology. Of particular interest is how cellular signals regulate chromatin remodeling with respect to the assembly of nuclear hormone receptors and DNA repair complexes. Genome instability is a common denominator for most, if not all, cancers, and misregulated signaling pathways are often the root cause for malignant transformation. Two central themes, 1) Cytoplasmic Signaling and Chromosome Dynamics and 2) Nuclear Signaling and Chromosome Stability, integrate a distinguished group of investigators. The programmatic goals are: 1) Discovery of critical molecules involved in the signaling to and function of transcriptional and DNA repair/recombination complexes In cancer cells;2) Identification of critical molecules in signaling and function of transcription and DNA repair as potential predictive markers and therapeutic targets in cancer;3) Collaboration with other programs to facilitate translational research originating in the basic scientific discoveries of the Molecular Oncology Program. The program has 35 members from 10 different academic units of UC Davis and LLNL. It has 16 NCl-funded projects for $2.4 million ADC (total peer-reviewed funding, $10.7 million ADC). The group has 449 publications for the last funding period;22% are inter-programmatic and 10% are intra-programmatic

Public Health Relevance

): To Improve survival from cancer, more fundamental information must be gained. This program contributes to this task by discovering how cells alter the way In which they signal as they move from normal to cancer. The program also focuses on understanding how DNA Is repaired. DNA repair may initially stop cancers developing;however, after cancer is present, alterations in DNA repair may influence the tumor's response to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743639
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$19,487
Indirect Cost
$6,792
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24
Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24
Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4
Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9
Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6
Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25
Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8
Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49
Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40
Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6

Showing the most recent 10 out of 84 publications